These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17431124)

  • 1. Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate.
    Cutts SM; Swift LP; Pillay V; Forrest RA; Nudelman A; Rephaeli A; Phillips DR
    Mol Cancer Ther; 2007 Apr; 6(4):1450-9. PubMed ID: 17431124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance.
    Cutts SM; Nudelman A; Pillay V; Spencer DM; Levovich I; Rephaeli A; Phillips DR
    Oncol Res; 2005; 15(4):199-213. PubMed ID: 17822280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde.
    Cutts SM; Swift LP; Rephaeli A; Nudelman A; Phillips DR
    Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):431-47. PubMed ID: 16178771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts.
    Forrest RA; Swift LP; Evison BJ; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):809-16. PubMed ID: 23263186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
    Cutts SM; Rephaeli A; Nudelman A; Hmelnitsky I; Phillips DR
    Cancer Res; 2001 Nov; 61(22):8194-202. PubMed ID: 11719450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytotoxicity and DNA Cross-Linking in Cancer Cells from Combinations of Doxorubicin and Formaldehyde.
    Barthel BL; Mooz EL; Wiener LE; Koch GG; Koch TH
    J Med Chem; 2016 Mar; 59(5):2205-21. PubMed ID: 26881291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The power and potential of doxorubicin-DNA adducts.
    Cutts SM; Nudelman A; Rephaeli A; Phillips DR
    IUBMB Life; 2005 Feb; 57(2):73-81. PubMed ID: 16036566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence specificity of adriamycin-DNA adducts in human tumor cells.
    Cutts SM; Swift LP; Rephaeli A; Nudelman A; Phillips DR
    Mol Cancer Ther; 2003 Jul; 2(7):661-70. PubMed ID: 12883039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
    Taatjes DJ; Fenick DJ; Koch TH
    Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines.
    Engel D; Nudelman A; Levovich I; Gruss-Fischer T; Entin-Meer M; Phillips DR; Cutts SM; Rephaeli A
    J Cancer Res Clin Oncol; 2006 Oct; 132(10):673-83. PubMed ID: 16826403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barminomycin functions as a potent pre-activated analogue of Adriamycin.
    Moufarij MA; Cutts SM; Neumann GM; Kimura K; Phillips DR
    Chem Biol Interact; 2001 Nov; 138(2):137-53. PubMed ID: 11672697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural requirements for the formation of anthracycline-DNA adducts.
    Cutts SM; Parker BS; Swift LP; Kimura KI; Phillips DR
    Anticancer Drug Des; 2000 Oct; 15(5):373-86. PubMed ID: 11354313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.
    Cutts SM; Rephaeli A; Nudelman A; Ugarenko M; Phillips DR
    Curr Top Med Chem; 2015; 15(14):1409-22. PubMed ID: 25866273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
    Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
    Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine.
    Swift LP; Cutts SM; Rephaeli A; Nudelman A; Phillips DR
    Mol Cancer Ther; 2003 Feb; 2(2):189-98. PubMed ID: 12589036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair.
    Spencer DM; Bilardi RA; Koch TH; Post GC; Nafie JW; Kimura K; Cutts SM; Phillips DR
    Mutat Res; 2008 Feb; 638(1-2):110-21. PubMed ID: 17961607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
    Nudelman A; Levovich I; Cutts SM; Phillips DR; Rephaeli A
    J Med Chem; 2005 Feb; 48(4):1042-54. PubMed ID: 15715472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
    Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
    Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
    Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
    Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.